Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/4237
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Plasma-Lyte M and Dextrose (Injection, Solution)
|
| dailymed-instance:dosage |
As directed by a
physician. Dosage is dependent upon the age, weight and clinical
condition of the patient as well as laboratory determinations. Parenteral drug
products should be inspected visually for particulate matter and
discoloration prior to administration whenever solution and container
permit. All injections in
Viaflex' plastic containers are intended for intravenous administration
using sterile equipment. As reported in the
literature, the dosage and constant infusion rate of intravenous
dextrose must be selected with caution in pediatric patients,
particularly neonates and low weight infants, because of the increased
risk of hyperglycemia/hypoglycemia. Additives may be
incompatible. Complete information is not available. Those additives
known to be incompatible should not be used. Consult with pharmacist, if
available. If, in the informed judgment of the physician, it is deemed
advisable to introduce additives, use aseptic technique. Mix thoroughly
when additives have been introduced. Do not store solutions containing
additives.
|
| dailymed-instance:descripti... |
Plasma-Lyte' M and
5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
Type 2, USP) is a sterile, nonpyrogenic solution for fluid and
electrolyte replenishment and caloric supply in a single dose container
for intravenous administration. Each 100 mL contains 5 g Dextrose
Hydrous, USP*, 161 mg Sodium Acetate Trihydrate, USP
(CHNaO���3HO); 138 mg
Sodium Lactate (CHNaO), 119 mg
Potassium Chloride, USP (KCl), 94 mg Sodium Chloride, USP (NaCl), 37 mg
Calcium Chloride, USP (CaCl���2HO), and 30 mg
Magnesium Chloride, USP (MgCl���6HO). It contains
no antimicrobial agents. The pH is 5.0 (4.0 to 6.5). The pH is adjusted
with hydrochloric acid. Plasma-Lyte' M and
5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
Type 2, USP) administered intravenously has value as a source of water,
electrolytes, and calories. One liter has an ionic concentration of 40
mEq sodium, 16 mEq potassium, 5 mEq calcium, 3 mEq magnesium, 40 mEq
chloride, 12 mEq acetate, and 12 mEq lactate. The osmolarity is 377
mOsmol/L (calc). Normal physiologic osmolarity range is approximately
280 to 310 mOsmol/L. Administration of substantially hypertonic
solutions (���600 mOsmol/L) may cause vein damage. The caloric content is
180 kcal/L. The Viaflex'
plastic container is fabricated from a specially formulated polyvinyl
chloride (PL 146' Plastic). The amount of water that can permeate from
inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container
may leach out certain chemical components from the plastic in very small
amounts; however, biological testing was supportive of the safety of the
plastic container materials.
|
| dailymed-instance:clinicalP... |
Plasma-Lyte' M and
5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
Type 2, USP) has value as a source of water, electrolytes, and calories.
It is capable of inducing diuresis depending on the clinical condition
of the patient. Plasma-Lyte' M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
Type 2, USP) produces a metabolic alkalinizing effect. Acetate and
lactate ions are metabolized ultimately to carbon dioxide and water,
which requires the consumption of hydrogen cations.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:contraind... |
Solutions containing dextrose may be contraindicated in patients with known
allergy to corn or corn products.
|
| dailymed-instance:supply |
Plasma-Lyte' M and
5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
Type 2, USP) in Viaflex' plastic containers is available as shown below: Exposure of
pharmaceutical products to heat should be minimized. Avoid excessive
heat. It is recommended the product be stored at room temperature
(25��C); brief exposure up to 40��C does not adversely affect the
product.
|
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:genericMe... |
Sodium chloride, potassium chloride, magnesium chloride, calcium chloride, sodium acetate, sodium lactate and dextrose
|
| dailymed-instance:fullName |
Plasma-Lyte M and Dextrose (Injection, Solution)
|
| dailymed-instance:adverseRe... |
Reactions which may
occur because of the solution or the technique of administration include
febrile response, infection at the site of injection, venous thrombosis
or phlebitis extending from the site of injection, extravasation, and
hypervolemia. If an adverse
reaction does occur, discontinue the infusion, evaluate the patient,
institute appropriate therapeutic countermeasures, and save the
remainder of the fluid for examination if deemed necessary.
|
| dailymed-instance:warning |
Plasma-Lyte' M and
5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
Type 2, USP) should be used with great care, if at all, in patients with
congestive heart failure, severe renal insufficiency, and in clinical
states in which there exists edema with sodium retention. Plasma-Lyte' M and
5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
Type 2, USP) should be used with great care, if at all, in patients with
hyperkalemia, severe renal failure, and in conditions in which potassium
retention is present. Plasma-Lyte' M and
5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
Type 2, USP) should be used with great care in patients with metabolic
or respiratory alkalosis. The administration of lactate or acetate ions
should be done with great care in those conditions in which there is an
increased level or an impaired utilization of these ions, such as severe
hepatic insufficiency. Plasma-Lyte' M and
5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
Type 2, USP) should not be administered simultaneously with blood
through the same administration set because of the likelihood of
coagulation. The intravenous
administration of Plasma-Lyte' M and 5% Dextrose Injection (Multiple
Electrolytes and Dextrose Injection, Type 2, USP) can cause fluid and/or
solute overloading resulting in dilution of serum electrolyte
concentrations, overhydration, congested states, or pulmonary edema. The
risk of dilutional states is inversely proportional to the electrolyte
concentrations of the injection. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly
proportional to the electrolyte concentrations of the injection. In patients with
diminished renal function, administration of Plasma-Lyte' M and 5%
Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type
2, USP) containing sodium or potassium ions may result in sodium or potassium retention. Plasma-Lyte' M and
5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
Type 2, USP) is not for use in the treatment of lactic
acidosis.
|
| dailymed-instance:indicatio... |
Plasma-Lyte' M and
5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection,
Type 2, USP) is indicated as a source of water, electrolytes, and
calories or as an alkalinizing agent.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Plasma-Lyte M and Dextrose
|